Were N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
| Registrars: |
Capita Registrars |
| CEO: |
Nigel Theobald |
| Executive Director: |
Luke Cairns, David Templeton |
| Non-Executive Chairman: |
Chris Britten |
| Vice Chairman and CEO: |
Michael Palfreyman |
| Address: |
6th Floor, 60 Gracechurch Street, London, United Kingdom |
| Phone: |
|
| Fax: |
|
| Website: |
http://www.n4pharma.com/ |
| Email: |
|